Prot #CX-839-008: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Project: Research project

Project Details

StatusActive
Effective start/end date10/23/1810/23/21

Funding

  • Calithera Biosciences, Inc. (Prot #CX-839-008)